Ascentage Pharma: Trustee Buys 110,000 Shares for 2022 RSU Scheme at HK$33.37 Each

Bulletin Express

06/11

Ascentage Pharma Group International announced that the trustee of its 2022 Restricted Share Unit (RSU) Scheme purchased 110,000 existing shares on-market on 11 June 2026 to satisfy upcoming vesting of RSUs.

The transaction amounted to HK$3.67 million, implying an average consideration of HK$33.37 per share. The acquired shares represent approximately 0.03% of Ascentage Pharma’s total issued share capital.

Following this purchase, the trustee’s aggregate on-market holdings for the 2022 RSU Scheme increased to 2.62 million shares. Shares held by the trustee are subject to the scheme’s rules, and the trustee is not entitled to exercise voting rights attached to these shares.

No additional RSU awards have been granted beyond the initial allocation on 23 June 2022 and subsequent grants disclosed on 4 May 2023, 2 September 2024, 27 June 2025, 26 November 2025 and 20 April 2026.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1121548855"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1121548855\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1121548855?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-11 21:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121548855","market":"us","top_or_hot":-1,"title":"Ascentage Pharma: Trustee Buys 110,000 Shares for 2022 RSU Scheme at HK$33.37 Each","media":"Bulletin Express","content":"<p>Ascentage Pharma Group International announced that the trustee of its 2022 Restricted Share Unit (RSU) Scheme purchased 110,000 existing shares on-market on 11 June 2026 to satisfy upcoming vesting of RSUs.</p>\n<p>The transaction amounted to HK$3.67 million, implying an average consideration of HK$33.37 per share. The acquired shares represent approximately 0.03% of Ascentage Pharma’s total issued share capital.</p>\n<p>Following this purchase, the trustee’s aggregate on-market holdings for the 2022 RSU Scheme increased to 2.62 million shares. Shares held by the trustee are subject to the scheme’s rules, and the trustee is not entitled to exercise voting rights attached to these shares.</p>\n<p>No additional RSU awards have been granted beyond the initial allocation on 23 June 2022 and subsequent grants disclosed on 4 May 2023, 2 September 2024, 27 June 2025, 26 November 2025 and 20 April 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ascentage Pharma: Trustee Buys 110,000 Shares for 2022 RSU Scheme at HK$33.37 Each</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAscentage Pharma: Trustee Buys 110,000 Shares for 2022 RSU Scheme at HK$33.37 Each\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-06-11 21:42</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Ascentage Pharma Group International announced that the trustee of its 2022 Restricted Share Unit (RSU) Scheme purchased 110,000 existing shares on-market on 11 June 2026 to satisfy upcoming vesting of RSUs.</p>\n<p>The transaction amounted to HK$3.67 million, implying an average consideration of HK$33.37 per share. The acquired shares represent approximately 0.03% of Ascentage Pharma’s total issued share capital.</p>\n<p>Following this purchase, the trustee’s aggregate on-market holdings for the 2022 RSU Scheme increased to 2.62 million shares. Shares held by the trustee are subject to the scheme’s rules, and the trustee is not entitled to exercise voting rights attached to these shares.</p>\n<p>No additional RSU awards have been granted beyond the initial allocation on 23 June 2022 and subsequent grants disclosed on 4 May 2023, 2 September 2024, 27 June 2025, 26 November 2025 and 20 April 2026.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06855","symbol_name":"亞盛醫藥","start_time":0,"source_url":"","article_id":"1121548855","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121548855","pubTimestamp":1781185366,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Ascentage Pharma Group International announced that the trustee of its 2022 Restricted Share Unit (RSU) Scheme purchased 110,000 existing shares on-market on 11 June 2026 to satisfy upcoming vesting...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06855":"亚盛医药"},"translate_title":"亚盛医药：受讬人按每股33.37港元购买110,000股2022年受限制股份单位计划股份","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06855":1},"content_text":"Ascentage Pharma Group International announced that the trustee of its 2022 Restricted Share Unit (RSU) Scheme purchased 110,000 existing shares on-market on 11 June 2026 to satisfy upcoming vesting of RSUs.\nThe transaction amounted to HK$3.67 million, implying an average consideration of HK$33.37 per share. The acquired shares represent approximately 0.03% of Ascentage Pharma’s total issued share capital.\nFollowing this purchase, the trustee’s aggregate on-market holdings for the 2022 RSU Scheme increased to 2.62 million shares. Shares held by the trustee are subject to the scheme’s rules, and the trustee is not entitled to exercise voting rights attached to these shares.\nNo additional RSU awards have been granted beyond the initial allocation on 23 June 2022 and subsequent grants disclosed on 4 May 2023, 2 September 2024, 27 June 2025, 26 November 2025 and 20 April 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}